000 03681nam a22004215i 4500
999 _c10071
_d10071
001 10071
003 DE-He213
005 20210601040353.0
006 a||||fo|||| 00| 0
007 cr nn 008mamaa
008 171124s2018 gw | s |||| 0|eng d
020 _a9783319659213
024 7 _a10.1007/978-3-319-65921-3
_2doi
040 _bspa
_dES-VaUE
050 4 _aRC377 .P76
_b2018 EB
245 1 0 _aProgressive Multiple Sclerosis
_cedited by Alastair Wilkins
250 _a2nd ed. 2018
264 1 _aCham
_bSpringer International Publishing
_bImprint: Springer
_c2018
300 _aIX, 307 p. 21 illus., 6 illus. in color
_bonline resource
336 _2rdacontent
_aTexto (visual)
_btxt
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
_2rda
490 _aMedicine (Springer-11650)
505 0 _aGeneral introduction -- What is disease progression?- Clinical scales of disease progression and disability -- Primary progressive MS -- Epidemiology of progressive multiple sclerosis -- The neuropathology of progressive multiple sclerosis -- Mechanisms of disease progression -- Axonal injury -- Imaging disease progression -- Biomarkers of disease progression -- Symptomatic treatment for progressive multiple sclerosis -- Trials of licenced RRMS disease modifying therapies in progressive MS -- Trials of novel therapies specifically for progressive MS -- Rehabilitation -- Future therapies for progressive multiple sclerosis.
520 _aThis revised, updated second edition draws together the basic science, pathology, epidemiology and treatment possibilities in progressive multiple sclerosis. Each chapter addresses specific aspects of progressive multiple sclerosis providing an extensive review of the current literature and a discussion of the likely mechanisms of tissue injury relevant to the disease. New additions to the second edition include a description of clinical scales used to determine levels of disability; recent trials specifically directed at reducing disease progression; rehabilitation; and an in depth discussion of the similarities and differences between primary and secondary multiple sclerosis. The biological processes underlying disease progression are elucidated as are specific pathophysiological mechanisms. The basic science of axonal degeneration and the clinical understanding of progressive multiple sclerosis are discussed in the context of emerging and future therapies for disease progression as are trials which have been and will be conducted for progressive multiple sclerosis. An overview of biomarkers for the disease is included and existing symptomatic therapies for progressive multiple sclerosis are covered in detail. Progressive Multiple Sclerosis, Second Edition is ideal for both general neurologists and those with a specialist interest in multiple sclerosis. It will also be of interest to neurologists in training and other medical professionals treating this common disease.
653 0 _aNeurology.
653 0 _aInternal medicine.
653 0 _aFamily medicine.
700 1 _aWilkins, Alastair.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
_9106996
776 0 8 _iPrinted edition:
_z9783319659206
776 0 8 _iPrinted edition:
_z9783319659220
776 0 8 _iPrinted edition:
_z9783319881324
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-65921-3
_zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942 _2lcc
_cLE
998 _db
_feng
_ggw
_h0